What is Tricuspid Regurgitation (TR)?

The tricuspid valve is the heart valve that regulates blood flow between the right atrium and the right ventricle. TR occurs when the valve does not close properly and blood flows back into the right atrium.

12.7 million patients in Europe suffer  
from heart valve disease! 

Heart valve disease is one of the most serious heart complications, affecting more than 12.7 million patients in Europe. 
Over the past decade, innovative minimally invasive catheter-based solutions have been developed for the treatment of aortic and mitral valve disease, creating a rapidly growing transcatheter heart valve replacement market.



  • Strong clinical need for  
    transcatheter solutions for TR

  • High market potential that is  
    continuously growing

  • Strong and highly motivated team

  • Strong IP protection

  • Unique design for safe, easy and  
    quick treatment

TRiCares was founded in 2013 
as a medical device start-up

Headquartered in Paris, France, we run another office in Munich, Germany. The team’s vision is to bring to market a catheter-based tricuspid valve replacement system that will help patients suffering from severe TR without the need for open-heart surgery.

Press Releases